Renovorx, INC. (RNXT) — SEC Filings

Overview

Renovorx, INC. (RNXT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-3 filed on Apr 16, 2026: RenovoRx, Inc. filed an S-3 registration statement on April 16, 2026, indicating plans to offer and sell securities. The filing, with SEC Accession No. 0001493152-26-017111, details the company's intention to raise capital through the issuance of new shares or other securities. The specific amount a

Sentiment Summary

Across 35 filings, the sentiment breakdown is: 2 bearish, 32 neutral, 1 mixed. The dominant filing sentiment for Renovorx, INC. is neutral.

Filing Type Overview

Renovorx, INC. (RNXT) has filed 1 3, 3 4, 1 S-3, 1 D, 1 3/A, 18 8-K, 6 10-Q, 2 DEF 14A, 2 10-K with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (35)

• RenovoRx Files S-3 for Potential Securities Offering — S-3 · Apr 16, 2026 Risk: medium
  RenovoRx, Inc. filed an S-3 registration statement on April 16, 2026, indicating plans to offer and sell securities. The filing, with SEC Accession No. 00014931
• RenovoRx Files Form D for Exempt Securities Offering — D · Apr 9, 2026 Risk: medium
  RenovoRx, Inc. filed a Form D on April 9, 2026, to announce an exempt offering of securities. The filing does not specify the dollar amount of the offering or t
• 4 Filing — 4 · Apr 8, 2026
• RenovoRx, Inc. Files Form 4: Ownership Change Report — 4 · Mar 27, 2026 Risk: medium
  On March 25, 2026, RenovoRx, Inc. (CIK: 0001574094) filed a Form 4, reporting changes in beneficial ownership of securities. The filing details transactions rel
• RenovoRx Files Amendment to Beneficial Ownership Statement — 3/A · Mar 27, 2026 Risk: low
  This is an amendment (3/A) to an initial statement of beneficial ownership of securities filed by RenovoRx, Inc. on February 4, 2026. The filing was accepted on
• RenovoRx Files 8-K: Officer/Director Changes & Exhibits — 8-K · Mar 27, 2026 Risk: medium
  RenovoRx, Inc. filed an 8-K on March 27, 2026, reporting changes under Item 5.02 concerning the departure of directors or officers, election of directors, appoi
• RenovoRx Form 4: Insider ID Update, No Transaction Details — 4 · Mar 25, 2026
  This Form 4 filing, dated March 24, 2026, indicates a change in beneficial ownership for RenovoRx, Inc. (Issuer CIK: 0001574094). While the filing details the r
• VOLL MARK Becomes RenovoRx Insider, Files Initial Ownership Statement — 3 · Mar 25, 2026
  This filing, a Form 3, indicates that VOLL MARK has become an insider at RenovoRx, Inc. as of February 4, 2026. A Form 3 is an initial statement of beneficial o
• 8-K Filing — 8-K · Nov 14, 2025
• RenovoRx Losses Widen Amid Early Commercialization Push — 10-Q · Nov 13, 2025 Risk: high
  RenovoRx, Inc. reported a net loss of $2.912 million for the three months ended September 30, 2025, compared to a net loss of $2.471 million for the same period
• RenovoRx Losses Widen to $5.3M Amid Increased R&D, Equity Infusion Boosts Cash — 10-Q · Aug 14, 2025 Risk: high
  RenovoRx, Inc. reported a net loss of $5.3 million for the six months ended June 30, 2025, an increase from a net loss of $3.465 million for the same period in
• RenovoRx Files 8-K on Shareholder Vote — 8-K · Jun 25, 2025 Risk: medium
  RenovoRx, Inc. filed an 8-K on June 25, 2025, reporting on a shareholder vote. The filing indicates that the company held a meeting where security holders were
• RenovoRx Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  RenovoRx, Inc. filed its 10-Q for the period ending March 31, 2025. The company, focused on pharmaceutical preparations, reported financial data for the first q
• RenovoRx Files Definitive Proxy Statement — DEF 14A · Apr 30, 2025 Risk: low
  RenovoRx, Inc. filed its definitive proxy statement on April 30, 2025, for the fiscal year ending December 31, 2024. The filing, designated as DEF 14A, outlines
• RenovoRx, Inc. Files 2024 10-K — 10-K · Apr 1, 2025 Risk: medium
  RenovoRx, Inc. filed its 2024 10-K on April 1, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, based in Mou
• RenovoRx, Inc. Files 8-K for Material Agreement — 8-K · Feb 10, 2025 Risk: medium
  RenovoRx, Inc. announced on February 10, 2025, that it entered into a Material Definitive Agreement on February 6, 2025. The filing also includes other events a
• RenovoRx Files 8-K on Financials — 8-K · Nov 14, 2024 Risk: medium
  RenovoRx, Inc. filed an 8-K on November 14, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and e
• RenovoRx Files Q3 2024 10-Q Report — 10-Q · Nov 13, 2024 Risk: medium
  RenovoRx, Inc. filed its quarterly report for the period ending September 30, 2024. The company, incorporated in Delaware, operates in the Pharmaceutical Prepar
• RenovoRx Files 8-K: Procedural Update — 8-K · Sep 25, 2024 Risk: low
  RenovoRx, Inc. filed an 8-K on September 25, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financ
• RenovoRx Dismisses Auditor BDO USA, LLP — 8-K · Aug 16, 2024 Risk: medium
  RenovoRx, Inc. announced on August 16, 2024, that it has dismissed its principal independent registered public accounting firm, BDO USA, LLP, effective August 1
• RenovoRx Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
  RenovoRx, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter. Key
• RenovoRx Appoints Dr. Jonathan Lim to Board — 8-K · Jun 7, 2024 Risk: medium
  RenovoRx, Inc. announced on June 7, 2024, that its Board of Directors has appointed Dr. Jonathan Lim as a new director, effective immediately. Dr. Lim brings ex
• RenovoRx, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024 Risk: low
  RenovoRx, Inc. (RNXT) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. RenovoRx, Inc. filed a 10-Q report for the period ending March 31, 2024. The
• RenovoRx Changes Auditors — 8-K · May 3, 2024 Risk: medium
  RenovoRx, Inc. announced on May 3, 2024, that their independent registered public accounting firm, WithumSmith+Brown, PC, has resigned. The company is in the pr
• RenovoRx, Inc. Schedules 2024 Annual Meeting of Stockholders — DEF 14A · Apr 30, 2024 Risk: low
  RenovoRx, Inc. (RNXT) filed a Proxy Statement (DEF 14A) with the SEC on April 30, 2024. RenovoRx, Inc. will hold its 2024 Annual Meeting of Stockholders on June
• RenovoRx Prices $1.5M Registered Direct Offering — 8-K · Apr 18, 2024 Risk: medium
  RenovoRx, Inc. announced on April 18, 2024, that it entered into a securities purchase agreement on April 17, 2024, to sell approximately $1.5 million of its co
• RenovoRx, Inc. Files 8-K Report — 8-K · Apr 16, 2024 Risk: medium
  On April 16, 2024, RenovoRx, Inc. filed an 8-K report detailing an "Other Event." The filing does not provide specific details about the event itself, but it in
• RenovoRx Sells $1M in Stock — 8-K · Apr 15, 2024 Risk: medium
  On April 15, 2024, RenovoRx, Inc. filed an 8-K detailing an unregistered sale of equity securities. The company entered into a Securities Purchase Agreement on
• RenovoRx, Inc. Files 8-K: Material Agreement & Other Events — 8-K · Apr 9, 2024 Risk: medium
  On April 9, 2024, RenovoRx, Inc. reported the entry into a material definitive agreement. The company also disclosed other events and filed financial statements
• RenovoRx, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Apr 1, 2024 Risk: medium
  RenovoRx, Inc. (RNXT) filed a Annual Report (10-K) with the SEC on April 1, 2024. RenovoRx, Inc. filed its annual report on Form 10-K for the fiscal year ended
• RenovoRx Appoints Biotech Veteran Rothberg to Board — 8-K · Mar 14, 2024 Risk: medium
  RenovoRx, Inc. announced on March 14, 2024, a change in its board of directors. Specifically, Dr. Jonathan M. Rothberg has been appointed to the Board of Direct
• RenovoRx Faces Nasdaq Delisting, Appoints New CEO — 8-K · Feb 23, 2024 Risk: high
  RenovoRx, Inc. received a delisting notice from Nasdaq on February 16, 2024, due to its common stock closing below the minimum bid price of $1.00 for 30 consecu
• RenovoRx Director James Ahlers Resigns from Board, Committees — 8-K · Feb 9, 2024 Risk: low
  RenovoRx, Inc. announced on February 9, 2024, that James Ahlers resigned from its Board of Directors, effective February 5, 2024. Ahlers, who also served on the
• RenovoRx Files 8-K: Material Agreement & Officer Compensation Changes — 8-K · Jan 29, 2024
  RenovoRx, Inc. filed an 8-K on January 29, 2024, reporting a material definitive agreement and changes in compensatory arrangements for certain officers, with t
• RenovoRx Opts Out of EGC Accounting Transition Period — 8-K · Jan 2, 2024
  RenovoRx, Inc. filed an 8-K on January 2, 2024, reporting an event that occurred on December 26, 2023. This filing indicates that the company is an 'emerging gr

Risk Profile

Risk Assessment: Of RNXT's 29 recent filings, 3 were flagged as high-risk, 20 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Renovorx, INC.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: $885K
• Net Income: -$8.2M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $10.044M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Mountain View, California
• Dr. Jonathan Lim
• Dr. Jonathan M. Rothberg
• Dr. Mark Theeuwes
• Shaun Bagai
• James Ahlers

Industry Context

The medical device and biotechnology sector is characterized by high R&D costs, lengthy regulatory approval processes, and significant capital requirements. Companies like RenovoRx are focused on developing innovative delivery systems and therapies, often relying on external funding until commercialization and profitability are achieved. The competitive landscape includes established players and emerging biotechs, with success often hinging on clinical trial outcomes, regulatory clearance, and effective market penetration.

Top Tags

corporate-governance (6) · capital-raise (4) · 10-Q (4) · financials (3) · material-agreement (3) · RenovoRx (3) · insider-filing (2) · Biotechnology (2) · Oncology (2) · Medical Devices (2)

Key Numbers

• S-3 Document Size: 326089 — Size of the main S-3 filing document in bytes.
• Complete Submission Text File Size: 523274 — Size of the complete submission text file in bytes.
• 8-K Form Size: 43179 — Size of the main 8-K document in bytes
• Exhibit EX-10.1 Size: 71898 — Size of the attached exhibit in bytes
• Net Loss: $8.2M — for the nine months ended September 30, 2025, a 38.6% increase from $5.9M in 2024
• Revenue: $885K — for the nine months ended September 30, 2025, up from $0 in 2024
• Accumulated Deficit: $58.4M — as of September 30, 2025, indicating significant historical losses
• Cash and Cash Equivalents: $10.0M — as of September 30, 2025, up from $7.1M at December 31, 2024
• Net Cash from Financing: $10.8M — for the nine months ended September 30, 2025, funding operations
• Common Stock Shares Outstanding: 36,649,916 — as of November 12, 2025, up from 24,034,672 at December 31, 2024, indicating dilution
• Research and Development Expenses: $4.768M — for the nine months ended September 30, 2025, up from $4.449M in 2024
• Selling, General and Administrative Expenses: $4.806M — for the nine months ended September 30, 2025, up from $3.889M in 2024
• Proceeds from Equity Financing: $10.803M — net of issuance cost, for the six months ended June 30, 2025
• Total Operating Expenses: $6.161M — for the six months ended June 30, 2025, up from $5.510M in 2024
• Shares Outstanding: 36,645,884 — as of August 11, 2025, reflecting recent equity issuances

Forward-Looking Statements

• {"claim":"RenovoRx will appoint a new director to fill the vacancy left by James Ahlers.","entity":"RenovoRx, Inc.","targetDate":"2024-08-09","confidence":"medium"}
• {"claim":"The company's stock price will not be significantly impacted by this director's resignation, given the lack of stated disagreement.","entity":"RenovoRx, Inc. stock","targetDate":"2024-02-16","confidence":"high"}

Frequently Asked Questions